NASDAQ:ICCC ImmuCell (ICCC) Stock Price, News & Analysis → The 1,000X Crypto Playbook (From True Market Insiders) (Ad) Free ICCC Stock Alerts $5.02 -0.03 (-0.59%) (As of 03:22 PM ET) Add Compare Share Share Today's Range$5.02▼$5.0750-Day Range$4.90▼$5.3752-Week Range$4.26▼$6.05Volume3,827 shsAverage Volume7,809 shsMarket Capitalization$38.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get ImmuCell alerts: Email Address Ad True Market InsidersThe 1,000X Crypto PlaybookChris Rowe has created a “Crypto Playbook” that anyone can follow… potentially turning small investments into pers#1 Crypto for 2024, completely FREE. About ImmuCell Stock (NASDAQ:ICCC)ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Read More ICCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICCC Stock News HeadlinesApril 12, 2024 | americanbankingnews.comImmuCell (NASDAQ:ICCC) Stock Passes Above 200-Day Moving Average of $5.03April 12, 2024 | americanbankingnews.comImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average of $5.03April 17, 2024 | True Market Insiders (Ad)#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…April 10, 2024 | finanznachrichten.deImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024April 9, 2024 | msn.comImmuCell reports preliminary Q1 sales, stock climbs 7%April 9, 2024 | markets.businessinsider.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024April 9, 2024 | globenewswire.comImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024February 29, 2024 | finance.yahoo.comImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call TranscriptApril 17, 2024 | True Market Insiders (Ad)The 1,000X Crypto PlaybookChris Rowe has created a “Crypto Playbook” that anyone can follow… potentially turning small investments into persFebruary 28, 2024 | seekingalpha.comImmuCell Corporation (ICCC) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | globenewswire.comImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023February 16, 2024 | finance.yahoo.comImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023February 16, 2024 | globenewswire.comImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023January 9, 2024 | benzinga.comImmuCell Stock (NASDAQ:ICCC) Dividends: History, Yield and DatesJanuary 9, 2024 | finanznachrichten.deImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023January 8, 2024 | msn.comImmuCell says total sale for year ended December falls 6% Y/YJanuary 8, 2024 | finance.yahoo.comImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023November 15, 2023 | finance.yahoo.comImmuCell Corporation (NASDAQ:ICCC) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | seekingalpha.comImmuCell Corporation (ICCC) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | msn.comImmuCell GAAP EPS of -$0.12, revenue of $5.39MNovember 13, 2023 | finance.yahoo.comImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023November 7, 2023 | finance.yahoo.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023October 5, 2023 | finance.yahoo.comImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023September 5, 2023 | finance.yahoo.comImmuCell Corporation (ICCC) Stock Historical Prices & Data - Yahoo FinanceAugust 29, 2023 | finance.yahoo.comImmuCell Announces Submission of CMC Technical Section to the FDAAugust 11, 2023 | seekingalpha.comImmuCell Corporation (ICCC) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finance.yahoo.comImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023See More Headlines Receive ICCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/17/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:ICCC CUSIPN/A CIK811641 Webwww.immucell.com Phone(207) 878-2770Fax207-878-2117Employees74Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,780,000.00 Net Margins-33.05% Pretax Margin-33.02% Return on Equity-21.79% Return on Assets-13.16% Debt Debt-to-Equity Ratio0.42 Current Ratio2.73 Quick Ratio0.87 Sales & Book Value Annual Sales$17.47 million Price / Sales2.23 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book1.55Miscellaneous Outstanding Shares7,750,000Free Float7,263,000Market Cap$38.91 million OptionableNot Optionable Beta0.59 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael F. Brigham (Age 63)President, CEO, Principal Financial Officer, Treasurer, Secretary & Director Comp: $395.24kMs. Bobbi Jo Brockmann (Age 47)VP of Sales & Marketing and Director Comp: $323.52kElizabeth S. ToothakerDirector of Finance & Administration and ControllerMr. A. Gustavo ScaffaSenior Director of QualityJohn W. ZinckgrafDirector of Product DevelopmentKey CompetitorsAspira Women's HealthNASDAQ:AWHARCA biopharmaNASDAQ:ABIOVolitionRxNYSE:VNRXOncoCyteNASDAQ:OCXCardio DiagnosticsNASDAQ:CDIOView All CompetitorsInstitutional OwnershipNorthern Trust CorpBought 19,781 shares on 2/13/2024Ownership: 0.421%View All Institutional Transactions ICCC Stock Analysis - Frequently Asked Questions How have ICCC shares performed in 2024? ImmuCell's stock was trading at $5.09 at the start of the year. Since then, ICCC stock has decreased by 0.8% and is now trading at $5.05. View the best growth stocks for 2024 here. When is ImmuCell's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ICCC earnings forecast. How can I listen to ImmuCell's earnings call? ImmuCell will be holding an earnings conference call on Friday, May 10th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "2581533". How were ImmuCell's earnings last quarter? ImmuCell Co. (NASDAQ:ICCC) released its earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.15) EPS for the quarter. The biotechnology company earned $5.10 million during the quarter. ImmuCell had a negative net margin of 33.05% and a negative trailing twelve-month return on equity of 21.79%. What guidance has ImmuCell issued on next quarter's earnings? ImmuCell updated its first quarter 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.3 million-$7.3 million. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE). How do I buy shares of ImmuCell? Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ICCC) was last updated on 4/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe 1,000X Crypto PlaybookTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.